XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and Licensing Revenue (Tables)
 6 Months Ended
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summarized Collaboration and Licensing Revenues
The following table summarizes the amounts recorded as revenue in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and six months ended June 30, 2020 and 2019.
 Three Months Ended 
 June 30,		Six Months Ended 
 June 30,
2020201920202019
ZIOPHARM Oncology, Inc.$—  $533  $100  $1,699  
Oragenics, Inc.32  181  230  382  
Intrexon Energy Partners, LLC—  796  —  1,773  
Intrexon Energy Partners II, LLC—  420  —  924  
Fibrocell Science, Inc.4,210  2,462  14,573  2,845  
Harvest start-up entities (1)—  2,039  —  4,762  
Other73  19  133  36  
Total$4,315  $6,450  $15,036  $12,421  
(1)For the three and six months ended June 30, 2019, revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.
Summary of Deferred Revenue Deferred revenue consisted of the following:
June 30,
2020		December 31,
2019
Collaboration and licensing agreements$36,152  $50,593  
Prepaid product and service revenues3,033  2,805  
Other265  435  
Total$39,450  $53,833  
Current portion of deferred revenue$6,592  $5,697  
Long-term portion of deferred revenue32,858  48,136  
Total$39,450  $53,833  
Summary of Deferred Revenue by Collaborator The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of June 30, 2020 and December 31, 2019, as well as the estimated remaining performance period as of June 30, 2020.
Average Remaining Performance Period (Years)June 30,
2020		December 31,
2019
Oragenics, Inc.3.9$2,823  $2,864  
Intrexon Energy Partners, LLC3.78,362  8,362  
Intrexon Energy Partners II, LLC4.412,843  12,843  
Fibrocell Science, Inc.1.03,308  17,697  
Harvest start-up entities (1)4.76,993  6,993  
Other2.31,823  1,834  
Total$36,152  $50,593  
(1)As of June 30, 2020 and December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.